David S. Warren

Array ( [id] => 13793405 [patent_doc_number] => 20190010241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 16/104434 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16104434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273817 [patent_doc_number] => 20190134193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS [patent_app_type] => utility [patent_app_number] => 16/059662 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16059662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090507 [patent_doc_number] => 20200199240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/631655 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826595 [patent_doc_number] => 20190016782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => STABLE FORM OF SIGNAL CONVERTING PROTEIN FUSION PROTEINS, AND METHODS OF USE AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/027382 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16027382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17220711 [patent_doc_number] => 11173194 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-16 [patent_title] => Inotropic antibodies and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 15/985514 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 14442 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15985514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19310489 [patent_doc_number] => 12036283 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods [patent_app_type] => utility [patent_app_number] => 16/613757 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 99 [patent_no_of_words] => 28140 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13604111 [patent_doc_number] => 20180353604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 15/969896 [patent_app_country] => US [patent_app_date] => 2018-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15969896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522553 [patent_doc_number] => 20180312819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => PROTEIN INHIBITORS TO COMPLEMENT AND VEGF PATHWAYS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/965382 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13510473 [patent_doc_number] => 20180306779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => METHOD FOR EVALUATING ACTIVITY OF G PROTEIN-COUPLED RECEPTOR (GPCR) [patent_app_type] => utility [patent_app_number] => 15/957406 [patent_app_country] => US [patent_app_date] => 2018-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15957406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13415939 [patent_doc_number] => 20180259512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => Bioassay Method for Antibody Against Thyroid-Stimulating Hormone Receptor, Measurement Kit for the Antibody, and Novel Genetically Modified Cell for Use in the Bioassay Method or the Measurement Kit [patent_app_type] => utility [patent_app_number] => 15/954434 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368855 [patent_doc_number] => 20180235968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => EGFR MUTATIONS [patent_app_type] => utility [patent_app_number] => 15/954541 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586643 [patent_doc_number] => 20180344870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/951950 [patent_app_country] => US [patent_app_date] => 2018-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15951950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342877 [patent_doc_number] => 20180222978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => MUSCARINIC ACETYLCHOLINE RECEPTOR BINDING AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/939748 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15939748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18050706 [patent_doc_number] => 11524073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Anti-human ADRB3 monoclonal antibody and application thereof in disease diagnosis and treatment [patent_app_type] => utility [patent_app_number] => 15/933406 [patent_app_country] => US [patent_app_date] => 2018-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 106 [patent_no_of_words] => 39619 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15933406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314239 [patent_doc_number] => 20180208656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/926223 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15926223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440781 [patent_doc_number] => 20180271933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 15/918268 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15918268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16697889 [patent_doc_number] => 10948480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Immunity to folate receptors [patent_app_type] => utility [patent_app_number] => 15/918777 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 18 [patent_no_of_words] => 9335 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15918777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826649 [patent_doc_number] => 20190016809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => CXCR2 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/907208 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15907208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314257 [patent_doc_number] => 20180208665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => Anti-GITR Antigen-Binding Proteins and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 15/900168 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371979 [patent_doc_number] => 20180237530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS [patent_app_type] => utility [patent_app_number] => 15/894531 [patent_app_country] => US [patent_app_date] => 2018-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15894531 [rel_patent_id] =>[rel_patent_doc_number] =>)